Skip to main content
Delfa

← All trials/NCT02541734

GLP1-EX-GELO

CompletedPhase 1, PHASE2

Effect of Gelofusine on GLP1-receptor Imaging

Effect of Gelofusine on 111In-DTPA-AHX-Lys40-Exendin 4 Uptake in the Kidney

Asset

Exenatide

GLP-1 agonist

Listed sites

0

Recruiting sites

-

Actual enrollment

12

Study population

Healthy volunteers

Eligibility highlights

•BMI ≥30

Primary endpoint

•Renal uptake

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02541734
Org study IDNL50233.091.14
Secondary ID2014-003006-33

Timeline

Milestones

Study first posted2015-09-04estimated
Last update posted2017-05-31actual
Study start2015-08 (month precision)
Primary completion2017-05actual (month precision)
Study completion2017-05actual (month precision)

Assets

Investigational agents

Exenatide

Who this study enrolls

Healthy volunteers

Who can enroll

Minimum age18 Years
Maximum age60 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

•>= 18 years
•<= 60 years
•Normal renal function
•Normal glucose regulation
•BMI 17>30

Exclusion criteria

•Use of any medication affecting renal function
•Known hypersensitivity to one of the substances used
•Hypertension
•Oedema
•Hypervolaemia
•Heart failure
•Pregnancy or the wish to become pregnant within 3 months after participation of the study.
•Lactation
•History of anaphylaxis
•Liver disease defined as aspartate aminotransferase or alanine aminotransferase level more than 3 times the upper limit of normal range (45U/L)

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Renal / kidney
1
Other (unclassified)
1

Renal / kidney

1 endpoint
Primary/protocol endpoint

Renal uptake as measured by uptake of 111In-exendin-4 on SPECT images and without co-infusion of Gelofusine.

Time frame:up to 8 months

descriptive

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Pancreas uptake as measured by uptake of 111In-exendin-4 on SPECT images

Time frame:up to 8 months

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.